Setup

MeiraGTx (MGTX) filed an 8-K on April 16, 2026 disclosing two simultaneous transactions: a $93.3M public offering underwritten by BofA and Goldman Sachs at $9.00, and an Asset Purchase Agreement reacquiring bota-vec (botaretigene sparoparvovec, RPGR gene therapy) from J&J for $25M upfront + up to $415M milestones + high-double-digit royalty. The stock closed down 15.7% on 8.8x volume. Analyst consensus sits at $26 mean target with 8/8 buy ratings — those notes predate both disclosures.

What the filing says

Offering: 11,111,111 shares at $9.00 → $93.3M net, closing April 17. 45-day insider lock-up. ATM resumes May 17. Use-of-proceeds attests sufficient to "fund operating expenses and capital expenditure requirements, including potential commercial launches of bota-vec... and AAV-hAQP1... in each case if approved, into the second half of 2028."

Reacquisition: J&J returned all bota-vec rights. MGTX pays $25M upfront + up to $415M contingent. The prior $285M J&J commercial milestone cascade is extinguished. Cross-check: zero bota-vec or RPGR mentions in JNJ's last 20 8-Ks or last four earnings transcripts. J&J walked silently.

Not in the 8-K: the 3-year AAV-hAQP1 Phase 1 durability data presented April 7 to institutions under Rule 163B Testing-the-Waters. That data sits in the S-3 prospectus supplement filed same day.

What the market thinks

At the April 16 close ($9.48), back-solving from analyst $26 target and a ≈$4 cash-floor bear outcome:

P_market(bull) = ($9.48 − $4) / ($26 − $4) ≈ 25%

Factor-decomposition-derived P(clean BLA + approval + strong launch) across the haqp1 state distribution: 35%. Probability-weighted intrinsic across five independent factors: ≈$14.87, or +45–70% over 12–18 months (≈25–45% IRR). Edge: ≈10 percentage points, ≈ $1.65/share.

Forward idio Sharpe: 0.71. Borderline investable. %Idio variance is 65–70% — below the 75% threshold. XBI loading contributes ≈22% of variance.

Why the gap exists

1. Reacquisition not synthesized with offering. The Phase 3 LUMEOS primary failure (May 2025) and J&J's 11-month "evaluating strategic options" silence framed bota-vec as dead. MGTX's $25M repurchase — RMAT + BTD designations retained, FFB + 30 investigators publicly advocating — restores an asset J&J spent $100M+ developing. Small-cap same-day filings don't always get read together.

2. Solvency pivot not fully priced. December 31, 2025 balance sheet was technically insolvent (−$5.8M equity). The H2 2028 runway attestation is a structural reset; the market is absorbing it as a standard offering discount, not a thesis-reset multiple.

3. Analyst consensus is stale. 8/8 buys with $26 mean target predate this week's dilution and reacquisition. Notes will update; framing is overdue.

Risks (ranked)

1. Insider signal mixed. CEO Forbes sold 62,000 shares at $7.41 on March 24. Officer Naylor sold 27,661 at $9.36 on April 7 during the institutional roadshow. Form 4 transaction codes (P/S/F/M) not yet verified. If Forbes's sale is code S (open-market), the "insiders loaded up at trough" narrative weakens materially.

2. Phase 2 topline risk (Q4 2026). Base rate for BTD+RMAT pivotals with FDA-aligned endpoint: 55–70%. Our estimate: 60%.

3. Beacon VISTA competitive shutout. Enrollment complete, topline H2 2026. If laru-zova (full-length RPGR construct) hits primary endpoint cleanly, bota-vec regulatory optionality compresses. Our estimate: 45% probability.

4. Hologen close. $95M of $200M upfront remains contingent on Series A close. Structure unverified.

5. %Idio below threshold. XBI beta drag not hedged.

Catalysts

• 4/17/2026 — offering closes; S-3 supplement 3-year durability data
• 4/30/2026 — AQUAx2 enrollment completion target
• 5/12/2026 — Q1 earnings
• Q2 2026 — Hologen Series A close + definitive agreement
• H2 2026 — Beacon VISTA laru-zova topline
• Q4 2026 — AQUAx2 Phase 2 topline (the main event)
• 1H 2027 — BLA filing

What would change our mind

Bearish:

• S-3 supplement shows 3-year durability degrading materially from 1-year timepoint — intrinsic drops toward $6–8
• Form 4 verification confirms Forbes March 24 sale was code S — insider signal reverses
• Beacon VISTA hits primary endpoint cleanly in H2 2026 — bota-vec optionality near-zero
• Hologen Series A fails outright — $95M gap plus cascading doubt

Bullish:

• 3-year durability clean (no decline 1yr → 3yr) — P(bull) moves from 35% toward 45–50%
• MGTX announces bota-vec Phase 3 or BLA path with FDA alignment — adds $2–4/share
• Hologen Series A closes with full $95M received in Q2

Evidence